Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Trial Details

NCT ID

NCT06257394

Phase

PHASE2

Sponsor

Hyoung Jin Kang

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• Dasatinib(Sprycel) arm
• Non-Dasatinib(Sprycel) arm

Locations (sample)

• Daegu, South Korea|35.87102,128.60121
• Daejeon, South Korea|36.35022,127.3848
• Hwasun, South Korea|35.06125,126.98746
• Jeju City, South Korea|33.50972,126.52194
• Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

• Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:
• Philadelphia chromosome-positive t(9;22)(q34;q11) or
• Patients with failed remission who had blast \> 5% on bone marrow test after initial remission induction therapy or
• Hypodiploidy (Number of chromosomes \< 44 (less than 44)) or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.